PACE trial

The PACE trial was a large and controversial trial which compared the effects of cognitive behavioural therapy (CBT), graded exercise therapy (GET), adaptive pacing therapy, and specialist medical care for people with myalgic…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 6 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

The PACE trial was a large and controversial trial which compared the effects of cognitive behavioural therapy (CBT), graded exercise therapy (GET), adaptive pacing therapy, and specialist medical care for people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The results of the trial were published in 20111; the investigators reported that both CBT and GET were "moderately" effective at treating ME/CFS.

The results have been questioned due to methodological weaknesses in the study design. For instance, the definition of recovery was weakened after the data was collected, leading to a larger share of recovered participants. Analyses under the original protocol did not find significant effects and concluded that GET is potentially unsafe for patients with ME/CFS.

As of 2021, graded exercise therapy and cognitive behavioural therapy (intended as a treatment) are no longer recommended by the National Institute for Health and Care Excellence for people with ME/CFS.

Initial study and findings

The £5 million trial was funded by various branches of the UK government, including the Department for Work and Pensions. Notable authors include psychiatrists Michael Sharpe and Peter White, along with psychotherapist Trudie Chalder.

Controversies and criticism

After being published, the trial generated considerable criticism and concerns which were voiced through letters to the editor, patient groups, and groups of researchers and healthcare professionals. Lancet Editor Richard Horton defended the trial, calling the critics "a fairly small, but highly organized, very vocal and very damaging group of individuals who have, I would say, actually hijacked this agenda and distorted the debate so that it actually harms the overwhelming majority of patients."

The study continued receiving criticism from within the scientific community. Ronald Davis of Stanford University wrote, "I'm shocked that the Lancet published it […] The PACE study has so many flaws and there are so many questions you'd want to ask about it that I don't understand how it got through any kind of peer review".

In an analysis of the study's design, the mathematician Professor Rebecca Goldin wrote that "There were problems with the study on almost all levels […] the flaws in this design were enough to doom its results from the start."

Outcome switching

After the initial data was collected, the method for scoring the subjective primary outcome measures of patient reported physical functioning and patient reported fatigue was changed, i.e. it used a more sensitive measure of the same primary outcome. Outcome switching is a practice that can lead to bias and undermine reliability, as studies may cherry pick a statistically significant outcome.

According to the authors, the switch was done in order to "improve the variance of the measure" and was "approved by the independent PACE Trial Steering Committee and Data Monitoring and Ethics Committee". An analysis under the original protocol found no statistically significant difference in improvement rates.

The improvement rates in the GET and CBT groups were around 20%, rather than the 60% reported with switched outcomes. There was also a change in how recovery (a secondary outcome) was defined. One of the original requirements was that patients would need to score over 85 on a survey of physical functioning, indicative of what healthy working-age people score.

This was changed to a score of over 60. This meant that some were above 60 on this metric at the start of the trial, as the criterion for entry was a score of under 65.

However, no patients were counted as recovered at trial entry, as they also needed to not meet the Oxford, CDC or London criteria for ME/CFS any more, and rate their overall health as much or very much better in order to be classed as recovered. Recovery rates under the original protocol were much lower and no statistical difference was found between the groups.

Reanalysis

After the data was accessed through a Freedom of Information request, researchers published a reanalysis of the PACE trial data, and concluded that the CBT and GET treatments were "not effective and unsafe" and "potentially harmful". The full PACE trial data showed that the treatments did not result in patients being able to return to work or study, and that they were not able to walk significantly further after treatment.

The reanalysis using the original primary outcome measures still showed there was a small improvement in one of the two subjective measures at 52 weeks for the GET and CBT groups. However, this difference was not sustained in the long-term follow-up. The GET group experienced twice the rate of adverse outcomes compared to controls, hence the conclusion that the treatment may be unsafe.

Health Research Authority inquiry

The UK Health Research Authority began an inquiry into the PACE trial in 2018, in response to questions from MP Carol Monaghan. The inquiry looked into conflicts of interest, making data publicly available to other researchers, and whether changing the outcome measures was appropriate.

The HRA published its findings in January 20191, and found that the PACE trial exceeded transparency expectations, and there were no regulatory concerns regarding the conduct of the trial. They note that some of the other criticisms of the trial that were brought to their attention are outside their remit, so they are unable to comment on them.

Legacy and influence

The PACE trial was a major piece of evidence used by influential health authorities to recommend cognitive behavioural therapy and graded exercise therapy for people with ME/CFS, such as the CDC (US) and NICE (UK). After many years of controversy and criticism of the trial, the CDC (in 2017), then NICE (in 2021) stopped recommending graded exercise therapy and cognitive behavioural therapy (as a treatment). As of 2024, the Cochrane guidelines conclude that GET likely reduces fatigue for those diagnosed under older criteria sets, partially based on evidence from the PACE trial.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1361640672 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “PACE trial” revision 1361640672 · retrieved 2026-10-20 publication date (×2) · confidence 0.95 revision URL

Provenance

snapshot enwiki-001361640672 · captured 1782705105.0 · version history

Cite this page as: encyclopegia.org, “PACE trial”, snapshot enwiki-001361640672. https://encyclopegia.org/a/pace-trial